Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Compugen (CGEN) has released an update. Compugen reported strong third-quarter financial results for 2024, with a net profit of $1.3 million, a ...

In the third quarter, we received a $30 million maximum payment from Gilead for achieving the FDA IND clearance ... In ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Compugen Ltd. is a clinical-stage cancer immunotherapy company, pioneering computational target discovery to identify new drug targets and biological pathways ... largely due to milestone payments ...

In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

The drug, Ocaliva, will continue to be available in the U.S. under ... for the disease to be approved in the U.S. Since then, ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

SACO – Kenneth G. “Greg” McGrovern passed away on Nov. 7, 2024. He was 94. Born on July 31, 1930, in Portland, Maine, Greg ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...